Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate

ConditionColonoscopy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe First Affiliated Hospital of Zhengzhou University

About this trial

In recent years, with increasing research into antispasmodic agents, topical antispasmodics have attracted considerable attention due to their direct action on the gastrointestinal mucosa and relatively low incidence of adverse reactions. Menthol, a natural terpenoid compound found in peppermint oil, has been confirmed by numerous studies to possess spasmolytic properties. Existing evidence indicates that menthol relaxes intestinal smooth muscle and alleviates spasm symptoms by antagonizing L-type calcium channels on the smooth muscle cell membrane, thereby reducing calcium influx. Furthermore, it exhibits local analgesic effects and can attenuate visceral hypersensitivity. Some studies suggest that oral or topical administration of peppermint oil preparations may improve intestinal spasm during colonoscopy, highlighting its potential utility in digestive endoscopy procedures. Nevertheless, current research on the spasmolytic efficacy and safety of menthol solution when administered via endoscopic irrigation during colonoscopy remains limited, and high-quality clinical trials are urgently needed for validation. This study aims to investigate the effectiveness and safety of menthol solution in relieving intestinal spasm, thereby providing scientific evidence for optimizing colonoscopy procedures.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age between 18 and 75 years, regardless of gender;

Scheduled to undergo colonoscopy (for screening, diagnostic, or follow-up purposes);

Adequate bowel preparation quality (Boston Bowel Preparation Scale score ≥ 6);

Voluntarily signed informed consent and able to cooperate with completing study-related assessments.

Disqualifiers

Allergy to menthol, cyclodextrin, or related substances;

History of severe intestinal diseases (such as ulcerative colitis, Crohn's disease, intestinal perforation, intestinal obstruction, intestinal tumors, etc.);

Presence of severe dysfunction of vital organs such as the heart, liver, kidneys, or lungs, or coagulation disorders;

Pregnant or lactating women;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Endoscopic irrigation was performed using a 0.1% menthol solution combined with simethicone.

    Drug

    Preparation method: Normal saline was used as the solvent. Menthol cyclodextrin inclusion complex (containing 7.3% menthol) was accurately weighed at 6.85 g and dissolved in 500 ml of normal saline to prepare a 0.1% menthol solution. After complete dissolution, 5 g of simethicone was added to form an aqueous suspension.

  • Endoscopic irrigation was performed using an aqueous suspension prepared with simethicone and normal saline.

    Drug

    Preparation method: 5 g of simethicone was added to 500 ml of normal saline to form the aqueous suspension.

Treatment groups

440 Participants
are divided into 2 treatment groups
Group A: Menthol groupExperimental treatment 1 intervention
Group B: placebo groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of intestinal spasm

Intestinal spasm score: Score 1 (Excellent): No spasm; the lumen opening is greater than or equal to two-thirds of the maximum diameter. Score 2 (Moderate): Moderate spasm; the lumen opening is less than two-thirds of the maximum diameter. Score 3 (Poor): Severe spasm; the oral-side lumen cannot be visualized. The maximum diameter is defined as the diameter of the intestinal lumen when fully distended. Spasm incidence: The percentage of patients with an intestinal spasm score of 2 or 3 out of the total number of patients in the group.

Time frame
Day 0
2

adenoma detection rate (ADR)

ADR = (Number of patients with at least one adenomatous polyp detected / Total number of patients in the group) × 100%. Pathological diagnosis was used as the gold standard.

Time frame
Day 0

Secondary outcomes

1

Spasm inhibition rate

The percentage of patients whose lumen opening exceeded two-thirds of the maximum diameter within 30 seconds after water injection irrigation, relative to the total number of patients in the group.

Time frame
Day 0
2

Polyp detection rate (PDR)

PDR = (Number of patients with at least one polyp detected / Total number of patients in the group) × 100%.

Time frame
Day 0

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: